Summarized by Masters of Longevity from BioSpace - Funding.
Company secured funding to take two programmes into clinical proof-of-concept.
Key Takeaways
- T-Therapeutics raised $133 million in an oversubscribed Series B.
- Proceeds will fund two TCR‑CD3 bispecific programmes into clinic.
- The financing was co-led by Advent Life Sciences and British Business Bank.
